https://www.pharmafocuseurope.com/technotrends/kelun-biotechs-sac-tmt-and-tagitanlimab-receives-breakthrough
Kelun-Biotech's Sac-TMT and Tagitanlimab Receives Breakthrough Therapy Designation
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced that its TROP2-targeting antibody-drug conjugate, sacituzumab tirumotecan, combined with the...
breakthrough therapykelunbiotechsactmt
https://www.ocoque.com/kelun-biotechs-trop2-adc-skb264-sac-tmt-second-nda-accepted-by-npma-locally-advanced-or-metastatic-egfr-mutant-nsclc/
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or...
Aug 20, 2024 - CHENGDU, China, Aug. 20, 2024 /PRNewswire/ — On August 20, the new drug application (NDA) for the core product sacituzumab tirumotecan (sac-TMT, formerly...
kelunbiotechadcsactmt
https://kelurahan-kelun.madiunkota.go.id/index.php/2026/08/27/koordinasi-pavingisasi-jalan-makam-kelun/
Koordinasi Pavingisasi Jalan Makam Kelun
koordinasijalanmakamkelun